New research found that the medication spironolactone, often prescribed for hypertension (high blood pressure), may reduce the risk of heart failure in people recovering from a heart attack.
American Heart AssociationNov 18 2024 New research found that the medication spironolactone, often prescribed for hypertension , may reduce the risk of heart failure in people recovering from a heart attack . However, it did not significantly reduce the number of deaths or other severe heart-related events, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024. The meeting, Nov.
The CLEAR SYNERGY trial included more than 7,000 adults in 14 countries who had experienced a severe heart attack. The trial's focus was to determine whether the routine use of spironolactone after a heart attack — regardless of whether the person had heart failure — could provide broader benefits in reducing the incidence of heart failure and death. Spironolactone is a mineralocorticoid receptor antagonist medication that blocks certain hormones.
The study was a randomized, double-blind, placebo-controlled clinical trial with four groups: spironolactone and colchicine - an anti-inflammatory medication; spironolactone and a placebo; colchicine and a placebo; or two placebos."While spironolactone didn't reduce deaths or other major heart complications after a heart attack, it did reduce the likelihood of heart failure, which is an important finding for patients and health care professionals," said Sanjit Jolly, M.D., M.Sc.
Participants fared much better in this trial than in previous ones. This reflects the advances in angioplasty techniques in the overall care for heart attacks. Modern treatment approaches, including medication, stent technology and more timely interventions, have positively impacted patient outcomes."
Sanjit Jolly, M.D., M.Sc., lead author of the trial and scientist at the Population Health Research InstituteThe research group highlighted several key study limitations. Women and people of different races and ethnicities were underrepresented in the participant pool, therefore, the results may not be generalizable to the larger population. The side effects of colchicine could have influenced a participant's decision to stop taking spironolactone.
Blood Pressure Heart Heart Failure Colchicine Heart Attack High Blood Pressure Placebo Research Stroke
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Area set for multi-million pound transformation with new hotel, new library and new homesProposals have also been submitted for the demolition of numerous Knowsley Council buildings in the Huyton area
Read more »
1950’s sugar rationing policies reduced risks of hypertension and diabetesThe study links early-life sugar exposure to chronic disease risk, suggesting that sugar restriction could enhance health and reduce diabetes and hypertension.
Read more »
Hypertension treatment hurts quality of life, especially for womenThis research uncovers the complex relationship between blood pressure treatment and mental health, advocating for personalized care to enhance quality of life.
Read more »
Getting enough sleep linked to lower hypertension risk in teensAdolescents who meet the recommended guidelines of nine to 11 hours of sleep per day were shown to have a significantly lower risk of hypertension, according to a new study from UTHealth Houston.
Read more »
Vitamin D receptor activation slows cell overgrowth in pulmonary hypertensionThe study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in pulmonary arterial smooth muscle cells, potentially reducing disease severity in pulmonary arterial hypertension (PAH).
Read more »
Paul Pogba sends new nine-word message after landing new jobPaul Pogba is set to return to football in the new year but already has already hinted at a new job
Read more »